Literature DB >> 2660395

The human prostatic carcinoma cell line LNCaP and its derivatives. An overview.

G J van Steenbrugge1, M Groen, J W van Dongen, J Bolt, H van der Korput, J Trapman, M Hasenson, J Horoszewicz.   

Abstract

The FGC (fast growing colony) line, a derivative of the LNCaP cell line shares all the main characteristics, including its androgen dependence, described for the original LNCaP cultures. A number of sublines originated from the FGC line which were characterized with respect to their response to steroid-depleted serum and to the synthetic androgen, R1881. After subcloning the FGC line a series of clones was isolated with distinct patterns of androgen-responsiveness. Among the sublines and clones studied, the FGC, FGC-JB and FGC clone-9 were androgen-dependent, whereas subline LNO, R and presumably also FGC clone-22 were androgen-independent. Distinct morphological differences were observed between the cells of the various sublines and between clone-9 and 22. The LNCaP cell line, its descending sublines and clonal derivatives provide a suitable in vitro model for studying different aspects of androgen-responsiveness of human prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660395     DOI: 10.1007/bf00262024

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  22 in total

1.  Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.

Authors:  J S Horoszewicz; E Kawinski; G P Murphy
Journal:  Anticancer Res       Date:  1987 Sep-Oct       Impact factor: 2.480

2.  Establishment of a new prostatic carcinoma cell line (TSU-Pr1).

Authors:  T Iizumi; T Yazaki; S Kanoh; I Kondo; K Koiso
Journal:  J Urol       Date:  1987-06       Impact factor: 7.450

3.  Isolation of a human prostate carcinoma cell line (DU 145).

Authors:  K R Stone; D D Mickey; H Wunderli; G H Mickey; D F Paulson
Journal:  Int J Cancer       Date:  1978-03-15       Impact factor: 7.396

4.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

5.  Human prostatic epithelial cells in culture: clonal selection and androgen dependence of cell line EB 33.

Authors:  K Okada; I Laudenbach; F H Schroeder
Journal:  J Urol       Date:  1976-02       Impact factor: 7.450

6.  Potential therapeutic effect of adriamycin-monoclonal anti-prostatic acid phosphatase antibody conjugate on human prostate tumor.

Authors:  T Deguchi; T M Chu; S S Leong; J S Horozsewicz; C L Lee
Journal:  J Urol       Date:  1987-02       Impact factor: 7.450

7.  Expression of HLA-like structures on a permanent human tumor line PC-93.

Authors:  F H Claas; G J van Steenbrugge
Journal:  Tissue Antigens       Date:  1983-03

8.  Steroid hormone regulation of prostatic acid phosphatase expression in cultured human prostatic carcinoma cells.

Authors:  P Schulz; H W Bauer; F Fittler
Journal:  Biol Chem Hoppe Seyler       Date:  1985-11

9.  Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture.

Authors:  R Biswas; B K Vonderhaar
Journal:  Cancer Res       Date:  1987-07-01       Impact factor: 12.701

10.  Hormone dependency of a serially transplantable human prostatic cancer (HONDA) in nude mice.

Authors:  Y Z Ito; S Mashimo; Y Nakazato; H Takikawa
Journal:  Cancer Res       Date:  1985-10       Impact factor: 12.701

View more
  8 in total

1.  ProstaScint(R) Scan: Contemporary Use in Clinical Practice.

Authors:  Samir S Taneja
Journal:  Rev Urol       Date:  2004

2.  LNCaP-OM, a new androgen-resistant prostate cancer subline.

Authors:  M Platica; R S Verma; M J Macera; O Platica
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

3.  Cytogenetic characterization of several androgen responsive and unresponsive sublines of the human prostatic carcinoma cell line LNCaP.

Authors:  J J König; E Kamst; A Hagemeijer; J C Romijn; J Horoszewicz; F H Schröder
Journal:  Urol Res       Date:  1989

4.  Differential sensitivity of hormone-responsive and unresponsive human prostate cancer cells (LNCaP) to tumor necrosis factor.

Authors:  X Zhao; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1992

5.  Differentially expressed genes in hormone refractory prostate cancer: association with chromosomal regions involved with genetic aberrations.

Authors:  A P Stubbs; P D Abel; M Golding; G Bhangal; Q Wang; J Waxman; G W Stamp; E N Lalani
Journal:  Am J Pathol       Date:  1999-05       Impact factor: 4.307

6.  Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells.

Authors:  Kiera Rycaj; Eun Jeong Cho; Xin Liu; Hsueh-Ping Chao; Bigang Liu; Qiuhui Li; Ashwini K Devkota; Dingxiao Zhang; Xin Chen; John Moore; Kevin N Dalby; Dean G Tang
Journal:  Oncotarget       Date:  2016-03-22

7.  Differences in the Central Energy Metabolism of Cancer Cells between Conventional 2D and Novel 3D Culture Systems.

Authors:  Ryo Ikari; Ken-Ichi Mukaisho; Susumu Kageyama; Masayuki Nagasawa; Shigehisa Kubota; Takahisa Nakayama; Shoko Murakami; Naoko Taniura; Hiroyuki Tanaka; Ryoji P Kushima; Akihiro Kawauchi
Journal:  Int J Mol Sci       Date:  2021-02-11       Impact factor: 5.923

8.  Androgen receptor differentially regulates the proliferation of prostatic epithelial cells in vitro and in vivo.

Authors:  Shu Yang; Ming Jiang; Magdalena M Grabowska; Jiahe Li; Zachary M Connelly; Jianghong Zhang; Simon W Hayward; Justin M Cates; Guichun Han; Xiuping Yu
Journal:  Oncotarget       Date:  2016-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.